伐尼克兰与尼古丁贴片预防心血管事件复发的比较效果
本研究基于澳大利亚新南威尔士州2011-2017年因主要心血管事件或手术住院的患者队列,比较出院后90天内使用伐尼克兰或处方尼古丁替代疗法贴片对主要心血管不良事件(MACE)复发的影响。经倾向评分逆概率加权后,伐尼克兰组与贴片组的MACE风险无差异(aHR 0.99, 95%CI 0.82-1.19),且性别间无显著交互作用(交互p=0.098)。
要点
- 出院后使用伐尼克兰与尼古丁贴片在预防MACE复发方面无显著差异。
- 女性中伐尼克兰效果偏离无效值,但性别交互作用未达统计学显著。
- 选择戒烟药物时需综合考虑疗效与患者个体因素。
核心结论
- 伐尼克兰与处方尼古丁贴片在预防再发MACE风险上无差异(aHR 0.99, 95%CI 0.82-1.19)。
研究设计与样本
- 基于澳大利亚新南威尔士州常规收集的医院、药品分发和死亡数据的队列研究。
- 纳入2011-2017年因主要心血管事件或手术住院、出院后90天内配发伐尼克兰或处方尼古丁贴片的患者。
- 暴露定义采用类意向性治疗分析,使用倾向评分逆概率加权调整混杂。
- 伐尼克兰组844人(72%男性,75%<65岁),贴片组2446人(67%男性,65%<65岁)。
- 中位随访时间分别为2.93年和2.34年。
主要发现
- 加权后,伐尼克兰相对于贴片的MACE风险无差异(aHR 0.99, 95%CI 0.82-1.19)。
- 男性aHR 0.92(95%CI 0.73-1.16),女性aHR 1.30(95%CI 0.92-1.84),性别交互p=0.098。
临床怎么用
- 在选择戒烟药物时,可考虑伐尼克兰或尼古丁贴片对心血管二级预防的等效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the comparative effectiveness of postdischarge use of varenicline versus prescription nicotine replacement therapy (NRT) patches for the prevention of recurrent cardiovascular events and mortality and whether this association differs by sex. METHODS: Our cohort study used routinely collected hospital, pharmaceutical dispensing and mortality data for residents of New South Wales, Australia. We included patients hospitalised for a major cardiovascular event or procedure 2011-2017, who were dispensed varenicline or prescription NRT patches within 90day postdischarge. Exposure was defined using an approach analogous to intention to treat. Using inverse probability of treatment weighting with propensity scores to account for confounding, we estimated adjusted HRs for major cardiovascular events (MACEs), overall and by sex. We fitted an additional model with a sex-treatment interaction term to determine if treatment effects differed between males and females. RESULTS: Our cohort of 844 varenicline users (72% male, 75% <65 years) and 2446 prescription NRT patch users (67% male, 65% <65 years) were followed for a median of 2.93 years and 2.34 years, respectively. After weighting, there was no difference in risk of MACE for varenicline relative to prescription NRT patches (aHR 0.99, 95% CI 0.82 to 1.19). We found no difference (interaction p=0.098) between males (aHR 0.92, 95% CI 0.73 to 1.16) and females (aHR 1.30, 95% CI 0.92 to 1.84), although the effect among females deviated from the null. CONCLUSION: We found no difference between varenicline and prescription NRT patches in the risk of recurrent MACE. These results should be considered when determining the most appropriate choice of smoking cessation pharmacotherapy.
引用
- Robijn, Filion, Woodward, et al. Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events. Heart. 2023. PMID: 36878673. doi:10.1136/heartjnl-2022-322170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。